Anti-Proteinuric Response to ACEI, ARB and Diuretics Combination.

Status

Terminated

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00200694

Enrollment

Registered

2005-09-20

Start date

2005-03-31

Completion date

2007-03-31

Last updated

2009-02-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heavy Proteinuria

Keywords

Proteinuria, ACEI, ARB, diuretics, blood pressure, renal failure

Brief summary

Determine the best strategy for proteinuria lowering in patients with proteinuria \> 1 g/day receiving ACEI and ARB combination: either increase of ACEI and ARB dosage or increase of diuretic dosage.

Interventions

DRUGramipril 5 mg + valsartan 80 mg/day + increased dosage of furosémide.

DRUGramipril 5 mg + valsartan 80 mg/day,

DRUGramipril 10 mg + valsartan 160 mg/day,

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* proteinuria \> 1 g/day with ramipril 5 + valsartan 80 mg/day for 2 months * proteinuria changes \< 50% on 3 separate dosages over 2 months.

Exclusion criteria

* age \< 18 or \> 80 years systolic BP \< 110 or ≥ 140 mmHg, serum creatinine \> 250 mmole/L * serum creatinine increase on ramipril + valsartan \> 20% * intolerance to ACEI or ARB

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026